Elise Stefanik’s ‘Hateful Rhetoric’ Ripped In Stinging Editorial By Hometown Newspaper

Herald morning quiz: September 20

Test your brains with the Herald’s morning quiz. Be sure to check back on nzherald.co.nz at 3pm for the afternoon quiz.

To challenge yourself with more quizzes, CLICK HERE.

MasterCraft Reduces Q1 Guidance; Reaffirms Full Year Guidance

MasterCraft Boat Holdings, Inc. (MCFT) said the company is revising first quarter guidance due principally to a temporary delay in the shipment of a key component from a single engine parts supplier for the MasterCraft brand. The company reaffirmed its guidance for fiscal 2022.

“By working closely with our supplier to resolve this temporary delay, we expect shipments of these key parts to resume early in the fiscal second quarter, enabling us to reaffirm our full year guidance,” said Fred Brightbill, CEO.

For the first-quarter, the company now expects adjusted earnings per share to decrease in the low-double digit percent range year-over-year, compared to the prior estimate of growth up in the low-20 percent range. The company now expects consolidated net sales growth to be up approaching the 30 percent range, compared to the prior estimate of up in the mid-30 percent range.

Shares of MasterCraft Boat Holdings were down 5% in pre-market trade on Friday.

Innate Pharma Surges 60% On Mid-stage Trial Results Of Lung Cancer

Shares of Innate Pharma S.A. (IPHA) are surging over 60% on Friday morning after its partner AstraZeneca Plc (AZN) presented results from the COAST Phase 2 trial during the European Society for Medical Oncology Congress 2021.

IPHA is currently trading at $9.23, up $3.48 or 60.52%, on the Nasdaq, on a volume of 47 million shares, above average volume of 1.2 million shares. The stock has traded between $3.02 and $11.86 in the year-to-date period.

The results showed monalizumab in combination with durvalumab improved progression-free survival and objective response rate compared to durvalumab alone in patients with Stage III non-small cell lung cancer.

Monalizumab, Innate’s lead partnered asset, is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor infiltrating cytotoxic CD8+ T cells and NK cells.

Broncos Report Card: Offense, defense do part after slow start to beat Jaguars – The Denver Post

Offense — B

Defense — B

Special teams — F

Coaching — B

WATCH: Broncos’ Pat Surtain II picks off Jaguars’ Trevor Lawrence for 1st NFL interception – The Denver Post

No Ronald Darby? No problem.

Broncos rookie cornerback Pat Surtain II had a sensational interception early in the fourth quarter, picking off Jaguars’ Trevor Lawrence’s deep pass.

It was Surtain’s first career interception. According to CBS Sports, his father Patrick Surtain also made his first interception in his second career NFL game.

The Broncos led 20-7 at the time.

Gold Edges Higher In Cautious Trade

Gold edged higher on Friday but still headed for a weekly decline as the dollar held firm ahead of next week’s FOMC meeting.

Spot gold rose 0.6 percent to $1,764.26 per ounce while U.S. gold futures were up 0.4 percent at $1,764.50.

Gold fell nearly 3 percent in the previous session as retail sales and jobless claims figures came in above expectations, giving ammunition to bets on early Fed tapering.

The dollar held close to a near three-week peak after a report from the Commerce Department showed that retail sales climbed by 0.7 percent in August after plunging by a revised 1.8 percent in July.

The rebound surprised economists, who had expected retail sales to decrease by another 0.8 percent compared to the 1.1 percent slump originally reported for the previous month.

A separate report from the Labor Department showed first-time claims for U.S. unemployment benefits rebounded by slightly more than expected in the week ended September 11th.

The Federal Reserve hold its next policy meeting on Tuesday and Wednesday, a session that will include the release of fresh economic projections and a new read on officials’ interest rate expectations.

Fuel and money matters

I am buying the Kia Sonet HTX, but am confused between the 1.0 turbo-petrol iMT and 1.5 diesel MT. Price difference between the two is low and the diesel has better mileage than the petrol. My monthly running will be approximately 1,000-1,100km.

Rakesh Sharma, Rohru

We feel the 1.5 diesel Sonet is a better choice than the 1.0 turbo-petrol because its smooth torque delivery makes it nicer to drive. Its overall refinement is surprisingly on par if not better than the petrol. Also, the diesel will be more fuel efficient, and you will get better range too for long trips. The only advantage of the 1.0 turbo-petrol is that it is an iMT, which is more convenient in traffic. If you do not mind a manual, however, go for the 1.5 diesel Sonet.

Hormazd Sorabjee is the editor of Autocar India. Mail your feedback and queries to [email protected]thehindu.co.in

Elise Stefanik’s ‘Hateful Rhetoric’ Ripped In Stinging Editorial By Hometown Newspaper

Rep. Elise Stefanik’s (R-N.Y.) hometown newspaper offered a scathing response to her anti-immigrant rhetoric in a recent ad campaign.

Stefanik, a Donald Trump loyalist, echoed the racist “great replacement” theory in ads warning voters of a “permanent election insurrection.” The conspiracy, which has been embraced by the far-right, posits that white people are being intentionally replaced by minorities and immigrants.

In an editorial published Friday, the board of Albany’s Times Union newspaper critically asked with its title, “How Low, Ms. Stefanik?”

“The idea of America as a melting pot is not some idealistic fiction of the left; it is part of the foundation of this nation’s greatness,” it wrote.

“If there’s anything that needs replacing in this country — and in the Republican Party — it’s the hateful rhetoric that Ms. Stefanik and far too many of her colleagues so seamlessly spew,” the editorial concluded. 

Read the Times Union’s full editorial here.

RELATED…